These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 26721620)

  • 21. Orexin supplementation in narcolepsy treatment: A review.
    Nepovimova E; Janockova J; Misik J; Kubik S; Stuchlik A; Vales K; Korabecny J; Mezeiova E; Dolezal R; Soukup O; Kobrlova T; Pham NL; Nguyen TD; Konecny J; Kuca K
    Med Res Rev; 2019 May; 39(3):961-975. PubMed ID: 30426515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Options for Narcolepsy.
    Barateau L; Lopez R; Dauvilliers Y
    CNS Drugs; 2016 May; 30(5):369-79. PubMed ID: 27155860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EFNS guidelines on management of narcolepsy.
    Billiard M; Bassetti C; Dauvilliers Y; Dolenc-Groselj L; Lammers GJ; Mayer G; Pollmächer T; Reading P; Sonka K;
    Eur J Neurol; 2006 Oct; 13(10):1035-48. PubMed ID: 16987156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electroencephalogram paroxysmal θ characterizes cataplexy in mice and children.
    Vassalli A; Dellepiane JM; Emmenegger Y; Jimenez S; Vandi S; Plazzi G; Franken P; Tafti M
    Brain; 2013 May; 136(Pt 5):1592-608. PubMed ID: 23616586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
    Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
    Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [NARCOLEPSY WITH CATAPLEXY: TYPE 1 NARCOLEPSY].
    Dauvilliers Y; Lopez R
    Rev Prat; 2016 Jun; 66(6):671-6. PubMed ID: 27538328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sodium oxybate on hypocretin/orexin and locus coeruleus neurons.
    Wu MF; Thannickal TC; Li S; McGregor R; Lai YY; Siegel JM
    Sleep; 2023 Sep; 46(9):. PubMed ID: 37155728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Narcolepsy: clinical approach to etiology, diagnosis, and treatment.
    Koziorynska EI; Rodriguez AJ
    Rev Neurol Dis; 2011; 8(3-4):e97-106. PubMed ID: 22249574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-invasive detection of narcolepsy type I phenotypical features and disease progression by continuous home-cage monitoring of activity in two mouse models: the HCRT-KO and DTA model.
    Piilgaard L; Rose L; Justinussen JL; Hviid CG; Lemcke R; Wellendorph P; Kornum BR
    Sleep; 2023 Sep; 46(9):. PubMed ID: 37210587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pathogenesis of narcolepsy: from HLA association to hypocretin deficiency].
    Klein G; Burghaus L; Diederich N
    Fortschr Neurol Psychiatr; 2012 Nov; 80(11):627-34. PubMed ID: 22696207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sleepiness that cannot be overcome: narcolepsy and cataplexy.
    Han F
    Respirology; 2012 Nov; 17(8):1157-65. PubMed ID: 22471619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in narcolepsy.
    Cao M
    Med Clin North Am; 2010 May; 94(3):541-55. PubMed ID: 20451031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of hypocretin based therapy in narcolepsy.
    Takenoshita S; Sakai N; Chiba Y; Matsumura M; Yamaguchi M; Nishino S
    Expert Opin Investig Drugs; 2018 Apr; 27(4):389-406. PubMed ID: 29623725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genetics and treatment of narcolepsy.
    Dauvilliers Y; Tafti M
    Ann Med; 2006; 38(4):252-62. PubMed ID: 16754256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain Circuits Underlying Narcolepsy.
    Pintwala SK; Peever J
    Neuroscientist; 2023 Dec; 29(6):751-766. PubMed ID: 34704497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypocretin (orexin) is critical in sustaining theta/gamma-rich waking behaviors that drive sleep need.
    Vassalli A; Franken P
    Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5464-E5473. PubMed ID: 28630298
    [No Abstract]   [Full Text] [Related]  

  • 37. Current and emerging options for the drug treatment of narcolepsy.
    De la Herrán-Arita AK; García-García F
    Drugs; 2013 Nov; 73(16):1771-81. PubMed ID: 24122734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging therapeutic targets for narcolepsy.
    Vringer M; Kornum BR
    Expert Opin Ther Targets; 2021 Jul; 25(7):559-572. PubMed ID: 34402358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment paradigms for cataplexy in narcolepsy: past, present, and future.
    Swick TJ
    Nat Sci Sleep; 2015; 7():159-69. PubMed ID: 26715865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deep brain stimulation of hypothalamus for narcolepsy-cataplexy in mice.
    Rogers AA; Aiani LM; Blanpain LT; Yuxian S; Moore R; Willie JT
    Brain Stimul; 2020; 13(5):1305-1316. PubMed ID: 32320748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.